Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Lillicrap

Showing results (91-100 of 132) with videos related to

Pageof 14
Sort By:
Journal of Thrombosis and Haemostasis : JTH|June 29, 2004
A novel type 2A (Group II) von Willebrand disease mutation (L1503Q) associated with loss of the highest molecular weight von Willebrand factor multimersL A O'Brien, J J Sutherland, C Hegadorn, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 15, 2011
Low prevalence of inhibitor antibodies in the Canadian haemophilia populationK E Webert, G E Rivard, J Teitel, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 18, 2015
Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profileD Lillicrap, A Schiviz, C Apostol, et al.
Journal of Thrombosis and Haemostasis : JTH|July 23, 2003
Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia AA Sharathkumar, D Lillicrap, V S Blanchette, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 22, 2014
Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010C Vézina, M Carcao, C Infante-Rivard, et al.
Journal of Thrombosis and Haemostasis : JTH|May 20, 2008
Influence of a GT repeat element on shear stress responsiveness of the VWF gene promoterC Hough, C L Cameron, C R P Notley, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 1, 2009
Undetected factor VIII in a patient with type 3 von Willebrands disease mistaken as severe haemophilia AA M Mullah-Ali, A K Chan, D Lillicrap, et al.
Journal of Thrombosis and Haemostasis : JTH|June 6, 2017
Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease miceL L Swystun, I Georgescu, J Mewburn, et al.
Journal of Thrombosis and Haemostasis : JTH|January 14, 2004
Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A miceB D Brown, C X Shi, F E M Rawle, et al.
Journal of Thrombosis and Haemostasis : JTH|January 15, 2013
The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant allelesM Bowman, A Tuttle, C Notley, et al.
Pageof 14

Showing results (91-100 of 132) with videos related to

Sort By:
Pageof 14
Journal of Thrombosis and Haemostasis : JTH|June 29, 2004
A novel type 2A (Group II) von Willebrand disease mutation (L1503Q) associated with loss of the highest molecular weight von Willebrand factor multimersL A O'Brien, J J Sutherland, C Hegadorn, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 15, 2011
Low prevalence of inhibitor antibodies in the Canadian haemophilia populationK E Webert, G E Rivard, J Teitel, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 18, 2015
Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profileD Lillicrap, A Schiviz, C Apostol, et al.
Journal of Thrombosis and Haemostasis : JTH|July 23, 2003
Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia AA Sharathkumar, D Lillicrap, V S Blanchette, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 22, 2014
Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010C Vézina, M Carcao, C Infante-Rivard, et al.
Journal of Thrombosis and Haemostasis : JTH|May 20, 2008
Influence of a GT repeat element on shear stress responsiveness of the VWF gene promoterC Hough, C L Cameron, C R P Notley, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 1, 2009
Undetected factor VIII in a patient with type 3 von Willebrands disease mistaken as severe haemophilia AA M Mullah-Ali, A K Chan, D Lillicrap, et al.
Journal of Thrombosis and Haemostasis : JTH|June 6, 2017
Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease miceL L Swystun, I Georgescu, J Mewburn, et al.
Journal of Thrombosis and Haemostasis : JTH|January 14, 2004
Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A miceB D Brown, C X Shi, F E M Rawle, et al.
Journal of Thrombosis and Haemostasis : JTH|January 15, 2013
The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant allelesM Bowman, A Tuttle, C Notley, et al.
Pageof 14